-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec publishes company presentation outlining drug discovery strategy and value-creation levers

PUBT·05/08/2026 17:54:50
Listen to the news
Evotec publishes company presentation outlining drug discovery strategy and value-creation levers
  • Evotec outlined mid-term value creation focused on above-market growth, operational cost-out, higher monetization at Just Evotec Biologics, upside from its co-owned asset pipeline.
  • Cost-out plan targets FY 2025 savings of more than EUR 60 million, including about 600 FTE reductions in D&PD from Mar 2024 to Jun 2025.
  • Biologics strategy pivots to more capital-efficient, asset-lighter model, supported by signed sale of Just Evotec Biologics EU Toulouse J.POD to Sandoz.
  • Deal terms include upfront payment of about USD 350 million in 2025, transition-period license, milestones and development revenues of more than USD 300 million for 2026-2028.
  • Evotec also flagged post-2028 royalties tied to 10 biosimilars, with six in technical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.